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Compared with its rodent orthologs, little is known
about the chemical specificity of human constitutive
androstane receptor (hCAR) and its regulation of he-
patic enzyme expression. Phenytoin (PHY), a widely
used antiepileptic drug, is a potent inducer of CYP2B6
in primary human hepatocytes, but does not activate
human pregnane X receptor (PXR) significantly in cell-
based transfection assays at the same concentrations
associated with potent induction of CYP2B6. Based on
this observation, we hypothesized that PHY may be a
selective activator of hCAR. In primary human hepato-
cytes, expression of CYP2B6 reporter genes containing
phenobarbital-responsive enhancer module (PBREM)
or PBREM/xenobiotic-responsive enhancer module
(XREM) response elements were activated up to 14- and
28-fold, respectively, by 50 M PHY. By contrast, parallel
experiments in HepG2 cell lines co-transfected with an
hPXR expression vector did not show increased re-
porter activity. These results indicated that a PXR-inde-
pendent pathway, which is retained in primary hepato-
cytes, is responsible for PHY induction of CYP2B6.
Further experiments revealed that PHY effectively
translocates hCAR from the cytoplasm into the nucleus
in both primary human hepatocytes and CAR/ mice.
Compared with vehicle controls, PHY administration
significantly increased CYP2B6 reporter gene expres-
sion, when this reporter construct was delivered to-
gether with hCAR expression vector into CAR/ mice.
However, PHY did not increase reporter gene expres-
sion in CAR/ mice in the absence of hCAR vector,
implying that CAR is essential for mediating PHY induc-
tion of CYP2B6 gene expression. Taken together, these
observations demonstrate that, in contrast to most of
the known CYP2B6 inducers, PHY is a selective activa-
tor of CAR in humans.
Induction of cytochrome P450 2B (CYP2B)1 expression by
xenobiotics, including clinically used drugs, is mediated by
activation of the nuclear receptors constitutive androstane re-
ceptor (CAR) and/or pregnane X receptor (PXR) through re-
sponse elements located in the promoter region of CYP2B
genes. In contrast to rodent CYP2B genes, mounting evidence
suggests that human PXR (hPXR) may be a key receptor in the
regulation of human CYP2B6 gene expression (1–3). hPXR
ligands, including rifampicin (RIF), phenobarbital (PB), trogli-
tazone, clotrimazole (CLZ), and SR12813 have been reported to
induce CYP2B6 gene expression (1, 4–7). Recently, fourteen
commercially available compounds, including weak, moderate,
and strong inducers of CYP2B6 and CYP3A4, were used to
compare the potency and magnitude of CYP2B6 and CYP3A4
induction and activation of hPXR in primary cultured hepato-
cytes and hepatoma cell-based reporter gene assays, respec-
tively. Results from these studies indicate that CYP2B6 induc-
tion is highly correlated with the activation of hPXR for most
compounds (3). Among the efficacious CYP2B6 inducers eval-
uated, most activate hPXR but not hCAR, such as RIF and CLZ
(CLZ was even reported as a hCAR deactivator by Moore et al.
(8)), whereas others can activate both hPXR and hCAR, such as
PB.
A notable exception is phenytoin (PHY), which exhibits effi-
cacious induction of CYP2B6 protein and mRNA in primary
cultured human hepatocytes at 50 M but relatively weak or
nonactivation of hPXR in several human hepatoma cell lines
(HepG2 and Huh7) at the same concentration (2). To our
knowledge, this would represent the first clinically applied
drug that might induce CYP2B6 through a PXR-independent
pathway. Our preliminary data demonstrated that PHY could
greatly activate CYP2B6 reporter gene expression in human
primary hepatocyte cultures transiently transfected with a
CYP2B6 luciferase reporter construct without co-transfection
of exogenous nuclear receptors. Because primary human hepa-
tocytes cultures but not hepatoma-immortalized cells maintain
the expression of most nuclear receptors, these results suggest
that transcriptional factors other than hPXR may be responsi-
ble for PHY induction of CYP2B6 within the range of tested
treatment concentrations. Based on these preliminary obser-
vations, we hypothesized that hCAR is the predominant regu-
lator of increased CYP2B6 gene expression by PHY in human
hepatocytes.
Although CAR plays an important role in the regulation of
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xenobiotic-inducible CYP genes, this nuclear receptor exhibits
a high level of constitutive transcriptional activity in immor-
talized cells and can accumulate spontaneously in nuclei (9).
Because of the unavailability of a cell system that can effec-
tively sequester CAR in the cytoplasm and decrease its consti-
tutive activation, it is difficult to study the mechanisms of CAR
activation. Accordingly, in the current study, we used primary
cultured human hepatocytes and CAR knockout mice as alter-
native systems to evaluate hCAR activation and translocation.
Cell line- and primary human hepatocyte-based transfection
assays were used to compare the activation profiles of PXR and
other nuclear receptors by PHY at the concentrations associ-
ated with efficacious induction of CYP2B6 protein and mRNA
expression levels in primary human hepatocytes. In vivo, PHY
activated hCAR in CAR knockout mice co-transfected with a
CYP2B6 reporter gene and an hCAR expression vector. Tail
vein injection of a florescence-tagged hCAR plasmid into CAR
knockout mice revealed that hCAR is localized in the cytoplasm
in untreated mouse livers but translocates to the nucleus after
treatment of mice with PHY or other known CAR activators.
Taken together, our results demonstrate for the first time that
PHY induction of human CYP2B6 is mediated predominantly
by CAR rather than PXR.
EXPERIMENTAL PROCEDURES
Materials—Phenytoin, rifampicin, phenobarbital, clotrimazole, dex-
amethasone, and collagenase type IV were purchased from Sigma.
6-(4-Chlorophenyl:imidazo[2,1-b]thiazole-5-carbaldehyde O-(3,4-dichlo-
robenzyl)oxime (CITCO) was obtained from BIOMOL (Plymouth Meet-
ing, PA). Cell culture media and charcoal-stripped fetal calf serum were
purchased from Invitrogen. The Dual-Luciferase Reporter Assay Sys-
tem was from Promega Co. (Madison, WI). Oligonucleotides were pur-
chased from Genosys, Inc. (The Woodlands, TX). Real-time RT-PCR
probes were from Applied Biosystems (Foster, CA).
Plasmid Constructs—Luciferase-CYP2B6 reporter gene constructs,
including pGL3-basic-PBREM, pGL3-basic-PBREM/XREM, and pGL3-
tk-(NR1)5 were generated as described previously (2, 10). hPXR expres-
sion vectors were obtained from Dr. Binfang Yan (University of Rhode
Island). pCR3-hCAR expression vector and fluorescent protein-tagged
hCAR (EYFP-hCAR) were constructed as described before (11, 12).
Human Primary Hepatocyte Cultures and Transfection Assays—
Liver tissues were obtained by qualified medical staff following donor
consent and prior approval from the Institutional Review Board at the
University of North Carolina at Chapel Hill. Hepatocytes were isolated
from human liver specimens by a modification of the two-step collagen-
ase digestion method as previously described (13). Hepatocytes were
plated at 3.75  105 cells/well into Biocoat® 24-well plates in 0.5 ml of
Dulbecco’s modified Eagle’s medium supplemented with 5% fetal calf
serum, antibiotics, insulin, and dexamethasone. After 4 h, cell culture
medium was changed to Williams’ E medium containing 6.25 g/ml
insulin, 6.25 g/ml transferrin, and 6.25 ng/ml selenium (ITS) and 0.1
M dexamethasone.
Transfection experiments were performed 24 h after cell seeding
using Effectene® transfection reagent (Qiagen) following the manufac-
turer’s instructions. Briefly, the transfection mixes contained 200 ng of
CYP2B6 reporter construct (pGL3 basic-CYP2B6 PBREM or pGL3 ba-
sic-CYP2B6 PBREM/XREM) and 25 ng of internal control plasmid
(pRL-TK Renilla luciferase). Transfected human primary hepatocytes
were treated with PHY (10, 20, and 50 M) or 0.1% Me2SO control for
24 h, respectively. Subsequently, luciferase activities were measured
with hepatocyte lysates using the Dual Luciferase Reporter reagents
according to the manufacturer’s instructions (Promega).
CYP2B6 induction experiments were performed in hepatocytes cul-
tured in collagen-coated 60-mm Permanox® culture dishes (Nalge Nunc
International) as described previously (13). Cultures were incubated for
36–48 h, followed by treatment with PHY (50 M), RIF (10 M), PB (1
mM), CLZ (10 M), and Me2SO (0.1%) for an additional 72 h. At the end
of the treatment period, microsomes and total RNA were isolated as
described before (2, 13).
Extraction of Nuclear Proteins—Preparation of nuclear extracts from
human primary hepatocytes were carried out as described previously
with modifications (14, 15). Briefly, hepatocytes (1  107) were scraped
into ice-cold phosphate-buffered saline and pelleted by centrifugation at
1500  g for 5 min. The resulting pellet was resuspended in 1 ml of
Buffer A (10 mM HEPES, 10 mM KCl, 1.5 mM MgCl2, 0.1 mM phenyl-
methylsulfonyl fluoride, and 1 mM dithiothreitol) with 0.3% Nonidet
P-40. After keeping on ice for 5 min, the cell suspension was homoge-
nized with a Kontes glass homogenizer (7 ml) B pestle, followed by
centrifugation at 1500  g for 5 min at 4 °C. After repeating the
resuspension and centrifugation steps, the supernatant was discarded
and 60 l of lysis buffer (10% glycerol, 10 mM HEPES, pH 7.6, 0.1 M KCl,
3 mM MgCl2, 0.1 mM EDTA, 1 g/ml pepstatin A, 1 g/ml leupeptin, 0.5
g/ml E-46, 1 mM Na3VO4, 0.1 mM phenylmethylsulfonyl fluoride, and
1 mM dithiothreitol) was added to the pellet for resuspension. The final
concentration was adjusted to 0.4 M by addition of the appropriate
volume of 5 M NaCl solution, mixed well, and vigorously shake at 4 °C
for 1 h. Finally, the lysates were centrifuged at 14,000 rpm for 10 min
at 4 °C, and the supernatant was transferred and stored at 80 °C.
Western Blot and Real-time RT-PCR—Microsomal or nuclear pro-
teins were separated on a NuPAGE Novex 4–12% Bis-Tris gel (Invitro-
gen) and electrophoretically transferred onto a polyvinylidene difluo-
ride blotting membrane. Subsequently, membranes were probed with
specific antibodies against CYP2B6 (Chemicon International) or hCAR
(generated as described by Yoshinari et al. (14)) and were incubated
with horseradish peroxidase-conjugated anti-rabbit IgG. Protein bands
were developed with ECL (Amersham Biosciences). For real-time RT-
PCR, the total RNA isolated from treated hepatocytes was reverse
transcribed to cDNA by using SuperScript II reverse transcriptase
(Invitrogen). CYP2B6 primers and TaqMan probe were designed using
Primer Express software (Applied Biosystems, Foster City, CA) as
reported before (2). CYP2B6 forward primer, 5-AAGCGGATTTGTCT-
TGGTGAA-3; reverse primer, 5-TGGAGGATGGTGGTGAAGAAG-3;
and probe, 6-carboxyfluorescein-CATCGCCCGTGCGGAATTGTTC-6-
carboxy-N,N,N,N-tetramethylrhodamine (TAMRA). For an internal
control, -actin mRNA was measured using Pre-Developed TaqMan
Assay Reagents for human -actin (PE Applied Biosystems, Foster
City, CA). For quantitative analysis, CYP2B6 mRNA was normalized to
-actin mRNA and expressed as -fold induction and compared with a
control mRNA value of one. Amplification and detection were performed
using the ABI Prism 7700 Sequence Detector system (Applied
Biosystems).
Transfection Assays in Hepatoma-derived Cell Lines—HepG2 and
Huh7 cells were cultured in 24-well plates at 5  104 cells/well in
Dulbecco’s modified Eagle’s medium, 24 h after seeded cells were co-
transfected with hPXR (50 ng), CYP2B6 reporter vector (100 ng) and
pRL-TK (10 ng) as internal control by using Effectene transfection
reagent (Qiagen). Transfected cells were treated with PHY (10, 20, and
50 M), RIF (10 M), PB (1 mM), CLZ (10 M), or 0.1% Me2SO as vehicle
control, respectively. 24 h later cells were harvested, and luciferase
activity was measured as described above.
In Vivo Gene Transfection and Confocal Imaging Analysis—A CAR-
null mouse (16) was first crossbred with C3H to generate CAR heterozy-
gous offspring. Subsequently, CAR heterozygous offspring were repeat-
edly backcrossed with C3H mice until the genetic background was over
95% C3H. The obtained heterozygous mice were bred to produce the
wild-type and CAR-null C3H mice. Animals weighing 23–25 g were
quarantined for 1 week before use in temperature- and humidity-con-
trolled rooms with a 12-h light/dark cycle. CYP2B6 reporter construct
(pGL3-basic-PBREM/XREM) (4 g) with or without pCR3-hCAR vector
(5 g) were injected into CAR/ mice through the tail vein using
TransIT in vivo gene delivery system (Mirus, Madison, WI) according to
the manufacturer’s protocol. Empty pCR3 vector was used to balance
the DNA amount in the injection without pCR3-hCAR, and pRL-SV40
(1 g) was used as internal control. PHY (100 mg/kg), PB (100 mg/kg),
CITCO (8 mg/kg), or equal volume of Me2SO as control was adminis-
tered intraperitoneally 3 h after gene delivery. Three animals for each
group were sacrificed 16 h after the treatment. Livers were homoge-
nized in 5 ml of passive lysate buffer (Promega), and 1 l of the
supernatant obtained by centrifugation at 4 °C was utilized for the dual
luciferase assay. For hCAR localization analysis, EYFP-hCAR (10 g)
was tail vein-injected into CAR/ mice using the same technique
described above. Two hours after the injection, PHY (100 mg/kg), PB
(100 mg/kg), CITCO (8 mg/kg), or Me2SO was intraperitoneally admin-
istered. A repeat dosage was given by the same route in 3 h. Mice were
sacrificed 7 h after tail vein delivery of hCAR. Mouse liver sections were
embedded into Tissue-Tek OTC and immediately frozen. Liver frozen
slide microscopic detection was carried out as reported previously (12,
17, 18). YFP images from liver sections were analyzed by confocal laser
scanning microscopy using a Zeiss LSM510 microscopy system. EYFP-
hCAR on the slides was excited at 514 nm, and YFP emission was
detected at 530 nm. A 100 oil immersion objective (1.4 numeric aper-
ture) was used for scanning with a pixel size of 0.06 m. More than 100
CAR-dependent Regulation of CYP2B6 by PHY29296
EYFP-hCAR expressed hepatocytes were counted for CAR localization
for each group. CAR subcellular localization was characterized as nu-
clear (N), cytosolic (C), and both nuclear and cytosol (NC).
RESULTS
PHY Induction of CYP2B6 Gene Expression in Primary Hu-
man Hepatocyte Cultures—To compare the extent of CYP2B6
induction by PHY and other prototypical inducers, primary
human hepatocytes were treated with PHY, PB, RIF, and CLZ
as described under “Experimental Procedures.” As shown in
two different preparations of human hepatocytes (HLN-131
and HLN-148), 50 M PHY induced CYP2B6 protein content by
8- and 20-fold, respectively (Fig. 1, A and B). Real-time RT-PCR
analysis showed that CYP2B6 mRNA expression levels were
induced 15-, 13-, 18-, and 12-fold over control by PHY, RIF, PB,
and CLZ, respectively (Fig. 1C). The extent of induction of
CYP2B6 expression in primary hepatocytes after treatment
with 50 M PHY is similar to other prototypical inducers at
both the protein and mRNA levels.
Activation of hPXR by Different CYP2B6 Inducers in Hepa-
toma Cell Lines—Transcriptional activation of the CYP2B6
gene is mediated synergistically by the PBREM and the distal
XREM present in the CYP2B6 promoter (10, 19). To examine a
correlation of the CYP2B6 induction in hepatocytes with hPXR
activation in hepatoma, CYP2B6 luciferase reporter constructs
containing PBREM, (NR1)5, or PBREM/XREM sequences were
co-transfected into Huh7 cells with a hPXR expression vector.
In agreement with previous reports (1, 2), the expression of
PBREM- or (NR1)5- reporter plasmids was effectively induced
by PB, RIF, and CLZ through activation of the co-transfected
hPXR. In contrast, little or no activation of hPXR was observed
after treatment with 50 M PHY (Fig. 2, A and B). In HepG2
cells stably transfected with hPXR, the expression of a tran-
siently transfected CYP2B6 homologous reporter construct
containing both the PBREM and XREM was increased after
treatment with PB (1 mM), RIF (10 M), and CITCO (1 and 3
M) but not after treatment with PHY (20 and 50 M) (Fig. 2C).
Based on these observations in Huh7 and HepG2 cells, further
investigations were performed in primary hepatocytes and
whole animals to determine whether human CAR played a role
in mediating PHY induction of CYP2B6.
PHY Activation of CYP2B6 Reporter Gene Expression in Pri-
mary Human Hepatocytes—In contrast to cell lines, cultured
primary human hepatocytes maintain the expression of most
endogenous transcription factors such as nuclear receptors,
including CAR, which sequesters in the cytoplasm under basal
conditions and translocates into the nucleus in response to
direct or indirect activators (12, 20). To examine the effects of
endogenous transcription factors on CYP2B6 reporter gene
expression, different CYP2B6 reporter gene constructs were
transfected into two separate preparations of primary human
hepatocytes cultured without transfection of exogenous nuclear
receptors. As indicated in Fig. 3 (A and B), 20 M PHY was
associated with 14- and 15-fold increases in the expression of
pGL3 basic-PBREM and pGL3 basic-PBREM/XREM reporter
constructs, respectively, whereas 21- and 28-fold increases
were observed with 50 M PHY. Notably, the extent of PHY-
induced expression of CYP2B6 reporter activity was similar to
the extent of induction of the endogenous CYP2B6 gene ob-
served in human primary hepatocytes.
PHY Translocates hCAR from Cytosol to Nucleus in Primary
Human Hepatocytes—Translocation of CAR from the cyto-
plasm to the nucleus is the initial step during its activation by
xenobiotics (21). The ability to identify efficacious CAR activa-
tors using cell-based transfection assays is complicated by the
spontaneous nuclear accumulation of CAR in transformed cell
lines such as HepG2 and Huh7 (18, 22). To investigate the
ability of PHY to activate hCAR, nuclear proteins were ex-
tracted from human primary hepatocytes treated with Me2SO,
PHY (50 M), RIF (10 M), or PB (1 mM) and subjected to
immunoblot analysis. Results showed that PHY and PB treat-
ment accumulated hCAR in the nucleus (Fig. 3C). In contrast,
FIG. 1. Induction of CYP2B6 in primary human hepatocytes. Human hepatocyte cultures were prepared from two different donors
(HLN-131 and HLN-148) and treated for 3 days with RIF (10 M), PHY (50 M), PB (1 mM), CLZ (10 M), or Me2SO as the vehicle control.
Hepatocyte homogenates (25 g) were prepared for CYP2B6 immunoblot analysis (A and B). Total RNA extracted from HLN-131 with the same
treatments as described above was subjected to real-time RT-PCR analysis of CYP2B6 mRNA expression level (C).
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RIF (a PXR activator) did not induce translocation of CAR to
the nucleus.
PHY Activates and Translocates hCAR in Vivo in Mouse
Liver—A previously described mouse tail vein gene delivery
technique was used to determine whether CYP2B6 reporter
constructs could be transactivated by hCAR in CAR/ mice
after treatment with PHY (12). Compared with vehicle treat-
ment, PHY, CITCO, and PB resulted in significant increases in
the expression of CYP2B6 reporter gene in CAR/ mice in-
jected with a CYP2B6 reporter construct and a hCAR expres-
sion vector (Fig. 4). In contrast, there were no significant
changes in CYP2B6 reporter gene expression after the same
treatments in CAR/ mice injected with the CYP2B6 reporter
construct in the absence of hCAR expression vector. These
results indicated that PHY activated hCAR in mouse liver,
leading to increase CYP2B6 reporter gene expression. In addi-
tion, the absence of effect in CAR/ mice injected with
CYP2B6 reporter construct alone indicates that other endoge-
nous nuclear receptors play minor roles in regulating PHY
induction of CYP2B6.
To determine whether PHY-induced expression of CYP2B6
reporter constructs in vivo involved nuclear translocation of
hCAR, fluorescent protein-tagged hCAR (EYFP-hCAR) was tail
vein-injected into CAR/ mice. The expression of fluorescently
labeled hCAR in the cytosol and nucleus was visualized under
a confocal microscopy. Of the hCAR-expressing cells counted in
the liver sections of vehicle-treated mice, 11% exhibited hCAR
localization in the nucleus, 83% in the cytoplasm, and 6% in the
cytoplasm and nucleus (mixed localization). In PHY- and PB-
treated mice, the majority of the EYFP-hCAR expression was
translocated into the nuclei of hepatocytes (73 and 70%, respec-
tively), whereas cytoplasmic localization decreased to 16 and
19%, respectively. Approximately 11% of the cells showed
mixed localization in mice treated with PHY or PB (Fig. 5). In
contrast, a previously reported hCAR activator (23), CITCO,
showed a relatively lower extent of hCAR nuclear translocation
in the current experimental system (33% in the nucleus, 50% in
the cytoplasm, and 17% as mixed localization) (Fig. 5). Overall,
there was an approximate 70% increase in the nuclear local-
ization of hCAR after PHY or PB treatment in CAR/ mice.
These results indicate that PHY is capable of inducing both the
nuclear translocation and activation of hCAR in the mouse
livers.
DISCUSSION
CAR regulation of CYP2B genes expression has been well
established in rodents (24, 25). Mouse CAR (mCAR) activators
such as TCPOBOP and PB can induce Cyp2b10 gene expres-
sion in both intact mouse liver and primary cultured mouse
hepatocytes. Induction of Cyp2b10 expression can be blocked
effectively by the mCAR repressors androstanol and androste-
nol. However, current knowledge is limited regarding the role
of hCAR in the regulation of human CYP2B gene expression.
To date, accumulated evidence suggests that the human
FIG. 2. Transactivation of CYP2B6 promoter constructs by human PXR in hepatoma cell lines treated with various inducers.
CYP2B6 reporter vectors containing PBREM or (NR1)5 were transfected into Huh7 cells together with hPXR expression vector as described under
“Experimental Procedures.” Transfected cells were treated for 24 h with RIF (10 M), PHY (50 M), PB (1 mM), CLZ (10 M), or Me2SO. Luciferase
activities were determined and expressed relative to controls (A and B). A CYP2B6 reporter construct containing both PBREM and XREM modules
was transiently transfected into a HepG2 cell line that stably expresses hPXR. Cells were treated for 24 h with RIF (10 M), PHY (20 and 50 M),
PB (1 mM), CITCO (1 and 3 M), or Me2SO. Luciferase activities were determined and expressed relative to controls (C). Data represent the mean 
S.D. (n  3).
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CYP2B6 gene is regulated in a PXR-dependent manner (1, 3,
26). The majority of known PXR activators are capable of
potently inducing CYP2B6 in primary human hepatocyte cul-
tures, including those that activate hPXR only (rifampicin,
hyperforin, and SR12813), those that activate both hPXR and
hCAR (PB), or those that activate hPXR but deactivate hCAR
(CLZ and ethynyl estradiol) (1, 3, 27). To our knowledge, the
current study is the first to demonstrate that a clinically used
drug such as PHY can induce CYP2B6 through a PXR-inde-
pendent pathway.
In vitro cell-based reporter assays have been used exten-
sively for screening chemical entities as activators of various
nuclear receptors (8, 28). Without exception in previous stud-
ies, compounds that activated hPXR in reporter assays in hep-
atoma cell lines also induced CYP2B6 in primary human hepa-
tocytes. Conversely, compounds that failed to activate did not
induce CYP2B6 (3). However, this study identifies PHY as an
exception to these previous observations. At 50 M, PHY in-
duces CYP2B6 in primary human hepatocytes with similar
efficacy as several prototypical inducers, including PB, RIF,
and CLZ. However, this same concentration of PHY does not
activate hPXR significantly in either HepG2 or Huh7 cells as
assessed by CYP2B6 reporter gene activity. These results are
in agreement with a previous report by Raucy et al. (29), where
only minor activation of PXR was observed with PHY at con-
centrations up to 1 mM in HepG2 cells (29). These initial results
provided the first inclination that hPXR may not be the pri-
mary mediator of PHY induction of CYP2B6 gene expression.
Compared with transformed cells, human primary hepato-
cyte cultures have been recognized as a more reliable in vitro
model for evaluating the induction of drug-metabolizing en-
zymes in human liver (30, 31). One possible reason for the
maintenance of xenobiotic inducibility of drug-metabolizing en-
zymes in primary but not transformed cells is the retention of
FIG. 3. PHY increases CYP2B6 reporter gene expression and translocates hCAR in primary human hepatocytes culture. Primary
human hepatocytes from two liver donors (HLN-199 and HLN-200) were seeded onto 24-well plates. Hepatocytes were transfected with CYP2B6
reporter vectors (pGL3-basic-PBREM or pGL3-basic-PBREM/XREM) then treated with PHY (10, 20, or 50 M). Dual luciferase activities were
measured following the manufacturer’s protocol (A and B). Hepatocytes cultured in 60-mm dishes were treated for 3 days with PHY (50 M), RIF
(10 M), PB (1 mM), or Me2SO. Nuclear extracts, prepared as described under “Experimental Procedures,” were subjected to Western immunoblot
analysis using hCAR antibody (C).
FIG. 4. Drug-induced expression of
a CYP2B6 reporter construct in
CAR/ mice in the presence and ab-
sence of hCAR. A CYP2B6 promoter
construct (pGL3-basic-PBREM/XREM)
was delivered into mice by tail vein injec-
tion, in the presence or absence of hCAR
expression vector, by using the TransIT
In Vivo Gene Delivery System as de-
scribed under “Experimental Proce-
dures.” Three hours after the injection,
PHY (100 mg/kg body weight), PB (100
mg/kg body weight), CITCO (8 mg/kg
body weight), or Me2SO was administered
intraperitoneally. Animals were sacri-
ficed 16 h afterward, and dual luciferase
assays were performed on liver lysates.
Data represent the mean  S.D. for each
treatment group (n  3 animals per
group).
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endogenous transcription factors in the former but not latter in
vitro model. In contrast to the results obtained from hepatoma
cell lines, treatment of primary hepatocytes with 20 or 50 M
PHY resulted in robust increases in CYP2B6 reporter expres-
sion in the absence of exogenously transfected nuclear receptor.
In agreement with our previous report, greater increases were
observed with transfection of the PBREM/XREM reporter con-
struct compared with the construct containing the PBREM
alone (10). These results in primary hepatocytes indicate that
PHY induction of CYP2B6 is regulated by transcription factors
other than PXR. Furthermore, these observations suggest that
primary hepatocytes are superior to cell lines in elucidating the
mechanisms regulating xenobiotic-mediated CYP gene expres-
sion due to retention of endogenous cellular and nuclear cofac-
tors required for transcriptional control.
Because studies in human hepatocytes implicated the role of
a nuclear receptor other than PXR in PHY-mediated induction
of CYP2B6, we considered hCAR as another likely candidate
because of the ability of its rodent counterpart to regulate
CYP2B induction and the known cross-regulation between it
and hPXR. Unlike the case for rodent CAR, greater difficulties
have been encountered in the evaluation of human CAR regu-
lation of target genes. Similar to its rodent counterparts, hCAR
spontaneously translocates to the nucleus in hepatoma cell
lines such as HepG2 and Huh7 independently of ligand binding
and/or activation. However, in contrast to its rodent counter-
parts, hCAR is not inhibited by mCAR repressors, such as
androgens, androstanol, progesterone, and calmodulin kinase
inhibitors (21). Furthermore, specific ligands identified for
mCAR, such as PB and TCPOBOP, have less selectivity for the
human receptor.
Although there are difficulties in using immortalized cells for
evaluating CAR function and activity, as described above, it
appears that primary human hepatocytes represent an alter-
native in vitro system for this purpose. Studies have shown
that CAR is compartmentalized in the cytoplasm of primary
hepatocytes and in vivo in the absence of ligands and/or acti-
vators (12). Translocation from the cytoplasm to the nucleus
has been considered the initial step of its activation. In exper-
iments conducted with human primary hepatocytes, we dem-
onstrated that PHY induces translocation of hCAR from the
cytoplasm to the nucleus to a similar extent as the known CAR
activator PB, whereas RIF, a known PXR activator, does not.
These observations indicate that PHY can initiate the first
required step of CAR activation in primary hepatocytes, lead-
ing to eventual up-regulation of CYP2B6 gene expression. To
further evaluate the role of hCAR in the regulation of PHY-
induced CYP2B6 gene expression, CAR/ mice were tran-
siently transfected with CYP2B6 reporter vectors alone or in
combination with hCAR expression vector. Results from these
in vivo experiments demonstrated that CAR is required for
PHY activation of CYP2B6 reporter gene expression. In the
absence of hCAR, PHY and other known CAR activators failed
to increase the expression of the transfected CYP2B6 reporter
gene, indicating that other endogenous transcription factors in
mice, including PXR, are not capable of mediating PHY-in-
duced CYP2B6 reporter gene expression in vivo. Using CAR-
null mice, a recent study by Jackson et al.2 identified PHY as a
new mCAR activator involved in the induction of murine
Cyp2b10 and Cyp2c29. PHY induces both Cyp2b10 and
Cyp2c29 expression in wild-type mice, but the induction was
dramatically reduced in CAR/ mice. These results suggest
that PHY induces murine Cyp2b10 and Cyp2c29 primarily via
the nuclear receptor CAR.
Confocal microscopic analysis using fluorescence-tagged
hCAR further confirmed that the majority of transfected hCAR
is expressed in the cytoplasm in the absence of CAR activators,
but that PHY and PB can induce efficient translocation of
hCAR into the nucleus. Therefore, PHY appears to be a selec-
tive activator for both human and mouse CAR. On the contrary,
CITCO, previously reported as a potent human CAR activator
(23), demonstrated a moderate capacity for fluorescence-tagged
hCAR nuclear translocation compared with PHY and PB.
About 11% of the nuclei expressed fluorescence-tagged hCAR
in the control animals, which may have contributed to the
higher basal expression of CYP2B6 reporter gene activity com-
pared with mice that received the CYP2B6 reporter gene alone.
In contrast to PXR, which requires direct ligand binding for
activation, CAR can be activated directly by compounds such as
TCPOBOP and CITCO, or indirectly by compounds such as PB
(8). An in vitro ligand binding assay indicated that PHY does
not bind hCAR or with very weak affinity,3 suggesting that
PHY activates hCAR through an indirect pathway in a manner
similar to PB.
PHY is a widely prescribed anticonvulsant drug used for the
prevention and treatment of seizures. Because it often is pre-
scribed chronically and co-administered with other therapeu-
tics, drug-drug interactions associated with PHY are common
(32, 33). In humans, PHY is predominantly metabolized by the
cytochrome P450 2C isozymes (80% by CYP2C9 and 20% by
CYP2C19) and is a recognized inducer of CYP2B6, CYP2C9,
and CYP3A4 (34–36). Because more than 40% of patients with
brain tumors experience disease-related seizures (37, 38), drug-
drug interactions between anticancer agents and antiepileptic
drugs such as PHY can have significant clinical consequences
(39). It has been reported that PHY induction of CYP2B6 re-
sults in altered pharmacokinetics of the antineoplastics cyclo-
phosphamide and ifosfamide, which are frequently co-admin-
istered with PHY (40, 41). Thus, PHY induction of liver
cytochrome P450 expression can result in decreased efficacy of
co-administered chemotherapeutics metabolized by CYP2B6.
However, to date, the mechanisms underlying PHY induction
of CYP2B6 have not been elucidated. Based on the results of
these studies, PHY is the first drug identified to cause drug
2 Jackson, J. P., Ferguson, S. S., Moore, R., Negishi, M., and
Goldstein, J. A. (2004) Mol. Pharmacol. 65, 1397–1404.
3 B. Goodwin, personal communication.
FIG. 5. Cellular localization of fluorescent protein-tagged
hCAR in CAR/ mice. A fluorescent-hCAR (EYFP-hCAR) was tail-
vein injected into CAR/ mice, treated with PHY (100 mg/kg body
weight), PB (100 mg/kg body weight), CITCO (8 mg/kg body weight), or
Me2SO intraperitoneally. Animals were sacrificed 7 h later, and frozen
liver sections were prepared for analysis by confocal microscopy as
described under “Experimental Procedures.” Images of liver sections
from mice treated with solvent (A), CITCO (B), and PHY (C) illustrating
EYFP-hCAR localization as: cytoplasm (C); mixed cytoplasm and nu-
clear (NC); or nuclear (N). The table shows the percentage of cells
exhibiting the different types of hCAR localization in mouse liver sec-
tions taken from each treatment group.
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interactions predominantly through activation of the nuclear
receptor CAR.
In summary, our data suggest that PHY induction of
CYP2B6 gene expression in human primary hepatocytes is
mediated predominantly through activation of human CAR,
not hPXR, indicating that multiple classes of CYP2B6 inducers
exist. PHY is the first clinically used drug to be identified as
inducing CYP2B6 through a PXR-independent pathway. More-
over, reporter assays conducted in primary human hepatocytes
most reliably reflect P450 regulation in vivo both qualitatively
and quantitatively compared with those conducted in cell lines.
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